Imaging and uptake mechanism of 131I-meta-iodobenzylguanidine in medullary thyroid carcinoma.
Authors:
- 1 January 1986
- journal article
- research article
- Published by Japan Endocrine Society in Endocrinologia Japonica
- Vol. 33 (3) , 309-315
Abstract
131I-meta-iodobenzylguanidine (131I-MIBG) was also taken up by medullary thyroid carcinoma (MTC) as well as by pheochromocytoma in two patients with Sipple''s syndrome. However, the mechanism of 131I-MIBG uptake by MTC has not been clarified yet. We measured tissue catecholamine levels in three MTC, since MTC can produce several active substances. Catecholamines were detected in various amounts in all MTC, but not in normal thyroid tissues. These finding suggest that MTC can produce catecholamines and therefore, 131I-MIBG is taken up and stored in catecholamine vesicles of MTC, like pheochromocytoma and neuroblastoma. We conclude that 131I-MIBG may be applied not only to diagnosis but also for the treatment of patients with MTC.Keywords
This publication has 3 references indexed in Scilit:
- Scintigraphic Localization of PheochromocytomaNew England Journal of Medicine, 1981
- Medullary Carcinoma of the Thyroid—A Cause of Cushing's Syndrome: Report of Two Cases1The Journal of Clinical Endocrinology & Metabolism, 1968
- Malignant Carcinoid Syndrome Associated with Noncarcinoid TumorsNew England Journal of Medicine, 1965